Cancer in Nursing Home Residents
Cancer in Elderly Nursing Home Residents in Belgium: Prospective Cohort Study Including Translational Research to Develop Better Prognostic Tools to Help With Treatment Decisions in the Elderly
Cancer is a disease of the elderly. Cancer incidence is 11-fold higher in persons over the age of 65, than in younger ones. Approximately 60% of all cancers and 70% of cancer mortality occurs in people older than 65 years. Moreover, due to the aging of the population in the Western world the number of elderly people is expected to increase and therefore the number of older cancer patients is expected to rise. Despite this rapid increase in cancer incidence and cancer-related mortality with age, our knowledge about ageing and cancer and about optimal treatment for older cancer patients is still far from adequate. Therefore, it is clear that cancer in the elderly is a major and increasing health problem. A key problem in geriatric oncology research is the important selection bias because very old/frail patients, are very rarely included in clinical trials.
Changes in the patterns of health care delivery have shifted the care of the elderly from acute care settings to the community and long-term care facilities. As the European population ages, more and more people will become nursing home residents, many of whom will have a suspicion of, or be diagnosed with, and eventually die from, cancer. Although cancer is very common in elderly nursing home residents, it is poorly studied. This lack of information may impact on clinical decision making and the appropriateness of treatments offered and therefore collection of this information is needed.
This project has two main objectives. The first objective is to report on demographics, referral patterns and motives for non-referral, anti-cancer treatments and outcome of patients in nursing homes with suspected or diagnosed active invasive cancer where a diagnostic or treatment decision has to be taken. The second objective is to develop better prognostic tools (for survival) including biological markers of ageing to help treatment decisions in the elderly.
研究概览
地位
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Mechelen、比利时
- Armonea nursing homes network
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
All individuals:
- Age ≥ 65 years
- Residents in a nursing home in the Armonea network in Belgium.
- Absence of any psychological, familial, or sociological condition potentially hampering compliance with the study protocol; those conditions should be discussed with the patient/proxy before registration in the study.
- Written informed consent must be given according to ICH/GCP, and national/local regulations.
- The treating general practitioner (GP) is willing to provide medical information required by the study.
Cancer patient cohort:
Patients must have a new cancer event defined as one of:
- A strong clinical suspicion (based on physician's judgement) of a new cancer where a diagnostic or therapeutic decision needs to be taken.
- A strong clinical suspicion (based on physician's judgement) of progression of a previously known cancer where a diagnostic or therapeutic decision needs to be taken.
- Diagnosis of a new cancer where a diagnostic or therapeutic decision needs to be taken.
- Diagnosis of progression of a previously known cancer where a diagnostic or therapeutic decision needs to be taken.
All invasive cancer types and all histologies are eligible. All lines of treatment are eligible. Patients who are diagnosed with cancer during routine medical examinations for some other medical condition
Control cohort:
• Absence of known active invasive cancer, or strong clinical suspicion of cancer (based on physician's judgement) at baseline.
Exclusion criteria:
Patients who were not suspected to have cancer (progression) in the nursing home, but are hospitalized for other (medical) reasons, are then diagnosed with cancer during hospitalization.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
Control cohort
Nursing home residents without cancer
|
|
Cancer patient cohort
Patients in nursing homes with suspected or diagnosed active invasive cancer where a diagnostic or treatment decision has to be taken
|
|
Biomarker cohort
Subgroup of individuals in the control cohort willing to provide a blood sample
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Prognostic capacity of p16INK4a expression in T lymphocytes on Overall Survival
大体时间:The analyses will be performed when 90 deaths will have been observed
|
The analyses will be performed when 90 deaths will have been observed
|
|
Demographics, referral patterns and motives for non-referral, anti-cancer treatments and outcome in nursing home patients with cancer or with strong clinical suspicion of cancer.
大体时间:Baseline, every 3 months and for max. 2 years
|
Baseline, every 3 months and for max. 2 years
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Comparison of baseline parameters and outcome between nursing home cancer patients (cancer patient cohort) and nursing home non-cancer patients (control cohort)
大体时间:Baseline, every 3 months and for max. 2 years
|
Baseline, every 3 months and for max. 2 years
|
|
Prognostic capacity of baseline clinical markers and Porock scale on OS, functional decline, cognitive decline and Quality of Life separately in nursing home cancer group (cancer patient cohort) and non-cancer group (control cohort).
大体时间:Baseline, every 3 months and for max. 2 years
|
Baseline, every 3 months and for max. 2 years
|
|
Prognostic capacity of other biomarkers of ageing on OS in the control group of nursing home patients without cancer.
大体时间:2 years
|
2 years
|
合作者和调查者
合作者
调查人员
- 学习椅:Hans Wildiers、UZ Leuven, Belgium
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- EORTC-1221
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.